Glioblastoma Multiforme Clinical Trial
— TaRRGETOfficial title:
A Phase II Trial of Tumor Treating Fields (TTFields) Concomitant With Radiosurgery for the Treatment of Recurrent, Bevacizumab-naïve Glioblastoma
Verified date | June 2023 |
Source | Prof. Franciszek Lukaszczyk Memorial Oncology Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
All patients will receive TTFields therapy and additionally Stereotactic Radiosurgery . Radiosurgery will be based on MRI and FET-PET or MRI alone. Addition of FET-PET will be preferred option.
Status | Active, not recruiting |
Enrollment | 40 |
Est. completion date | December 9, 2024 |
Est. primary completion date | July 20, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patient's written informed consent (IC) obtained at the latest the day after planning MRI; 2. Legal capacity: patient can understand the nature, significance, and consequences of the study; 3. Age =18 years (no upper age limit); 4. Karnofsky Performance Score (KPS) = 70; 5. Recurrence of GBM (WHO grade IV) based on RANO criteria or GBM after subtotal resection of recurrence with macroscopic residual tumor; 6. Histological confirmation of GBM at initial or secondary diagnosis; 7. Previous radiotherapy of glioma with a total dose of 59.4 - 60 Gy (single dose 1.8 - 2.0 Gy) and chemotherapy with temozolomide; 8. At least 6 months between the end of the first course of radiotherapy and radiosurgery; 9. Recurrent tumor visible on FET-PET and/or T1Gd-MRI, with the maximum diameter up to 5 cm by either technique (in case of multifocal tumors, the sum of all diameters must be 5 cm on FET-PET and T1Gd-MRI); 10. Start of TTFields before radiosurgery; 11. Disease free from other cancers for = 5 years; 12. Adequate haematologic, renal and hepatic function (absolute neutrophil count ?1000/mm3; haemoglobin ?100 g/L platelet count, ?100,000/mm3; serum creatinine level ?1.7 mg/dL (<150 µmol/L); total serum bilirubin level ? the upper limit of normal and liver-function values, <3 times the upper limit of normal); Exclusion Criteria: 1. Recent (= 4 weeks before IC) histological result showing no tumor recurrence; 2. Previous treatment of GBM with bevacizumab; 3. Chemotherapy or molecular targeted therapies planned before diagnosis of further tumor progression after study intervention 4. Simultaneous participation in other interventional trials which could interfere with this trial and/or participation in a clinical trial within the last thirty days before the start of this study and/or previous participation (randomization) in this study; 5. Pregnancy, nursing, or patient not willing to prevent a pregnancy during treatment; 6. Known or persistent abuse of medication, drugs or alcohol; 7. Known allergy against the MRI contrast agent gadolinium or the PET tracer 18F-FET or against any of the components; 8. Evidence of increased intracranial pressure (midline shift >5 mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness); 9. Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias. 10. Gross total resection of recurrence confirmed with postoperative MRI and negative FET-PET result 11. Other malignancies ,except for non-melanomatous skin cancers, or carcinoma in-situ of uterus, cervix or bladder |
Country | Name | City | State |
---|---|---|---|
Poland | The Franciszek Lukaszczyk Oncology Center | Bydgoszcz |
Lead Sponsor | Collaborator |
---|---|
Prof. Franciszek Lukaszczyk Memorial Oncology Center | NovoCure GmbH |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1-year survival rate | Survival will be measured from date of enrollment until date of death | 12 Months | |
Secondary | Radiation necrosis range | The percentage of patients who had radiation necrosis | 12 months | |
Secondary | Progression free survival (PFS) | PFS will be measured from the date of enrollment to date of progression (in months) based on RANO citeria. | 12 moths | |
Secondary | Steroid needs until treatment failure | The analysis will be performed based on the steroid doses reported in time of enrollment to date of progression or one year after | 12 months | |
Secondary | Patterns of failure | The analysis will be performed based on location of failure in relation to target volume | 12 months | |
Secondary | Objective response rates | The percentage of patients who had either complete response or partial response per RANO criteria following enrollment | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05023551 -
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
|
Early Phase 1 | |
Recruiting |
NCT06059690 -
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
|
Phase 1/Phase 2 | |
Recruiting |
NCT04116411 -
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
|
Phase 2 | |
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00038493 -
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
Recruiting |
NCT01923922 -
CT Perfusion in the Prognostication of Cerebral High Grade Glioma
|
N/A | |
Completed |
NCT01956734 -
Virus DNX2401 and Temozolomide in Recurrent Glioblastoma
|
Phase 1 | |
Completed |
NCT01301430 -
Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
|
Phase 1/Phase 2 | |
Suspended |
NCT01386710 -
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
|
Phase 1/Phase 2 | |
Completed |
NCT01402063 -
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
|
Phase 2 | |
Active, not recruiting |
NCT00995007 -
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
|
Phase 2 | |
Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Terminated |
NCT00990496 -
A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)
|
Phase 1 | |
Completed |
NCT00402116 -
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00504660 -
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
|
Phase 2 | |
Recruiting |
NCT05366179 -
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
|
Phase 1 |